Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDS Aridis Pharmaceuticals	$0.00 +∞	$0.00	$0.00 ▼ $0.07	$5K	11.59	9,093 shs	1,950 shs
ASLN ASLAN Pharmaceuticals	$0.60	$0.60	$0.48 ▼ $25.44	$1.23M	1.4	122,322 shs	N/A
CPIX Cumberland Pharmaceuticals	$3.50 +2.9%	$4.60	$1.04 ▼ $7.25	$52.36M	-0.39	869,482 shs	78,285 shs
ETTX Entasis Therapeutics	$2.19	$2.19	$1.40 ▼ $3.88	$104.80M	1.33	239,104 shs	800 shs
TRVN Trevena	$0.93 +2.1%	$1.09	$0.73 ▼ $7.85	$894K	0.61	2,077 shs	543 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDS Aridis Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-99.83%
ASLN ASLAN Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-76.47%
CPIX Cumberland Pharmaceuticals	+13.33%	+11.84%	-35.11%	-17.07%	+128.19%
ETTX Entasis Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
TRVN Trevena	-2.44%	+0.26%	-10.55%	-17.80%	-84.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARDS Aridis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ASLN ASLAN Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CPIX Cumberland Pharmaceuticals	0.8861 of 5 stars	0.0	5.0	0.0	0.0	1.6	1.7	0.0
ETTX Entasis Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRVN Trevena	1.7175 of 5 stars	3.0	3.0	0.0	0.0	2.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDS Aridis Pharmaceuticals	0.00	N/A	N/A	N/A
ASLN ASLAN Pharmaceuticals	0.00	N/A	N/A	N/A
CPIX Cumberland Pharmaceuticals	0.00	N/A	N/A	N/A
ETTX Entasis Therapeutics	0.00	N/A	N/A	N/A
TRVN Trevena	2.00	Hold	$5.00	436.48% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDS Aridis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
ASLN ASLAN Pharmaceuticals	$12M	0.10	N/A	N/A	($6.50) per share	-0.09
CPIX Cumberland Pharmaceuticals	$41.08M	1.27	$0.30 per share	11.66	$1.61 per share	2.17
ETTX Entasis Therapeutics	$7M	14.97	N/A	N/A	$0.66 per share	3.32
TRVN Trevena	$443K	2.02	N/A	N/A	($11.07) per share	-0.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDS Aridis Pharmaceuticals	-$30.37M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ASLN ASLAN Pharmaceuticals	-$44.22M	-$21.92	N/A	∞	N/A	N/A	-8,454.87%	-121.60%	N/A
CPIX Cumberland Pharmaceuticals	-$6.48M	-$0.25	N/A	∞	N/A	-7.98%	6.92%	2.33%	8/5/2025 (Estimated)
ETTX Entasis Therapeutics	-$47.14M	-$1.12	N/A	N/A	N/A	N/A	-145.48%	-103.75%	N/A
TRVN Trevena	-$40.29M	-$47.04	N/A	N/A	N/A	N/A	N/A	-119.55%	8/6/2025 (Estimated)

Latest ARDS, ASLN, TRVN, CPIX, and ETTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/6/2025	Q1 2025	CPIX Cumberland Pharmaceuticals	N/A	$0.15	N/A	$0.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDS Aridis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ASLN ASLAN Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CPIX Cumberland Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ETTX Entasis Therapeutics	N/A	N/A	N/A	N/A	N/A
TRVN Trevena	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDS Aridis Pharmaceuticals	N/A	N/A	N/A
ASLN ASLAN Pharmaceuticals	N/A	1.05	1.05
CPIX Cumberland Pharmaceuticals	0.18	1.25	1.09
ETTX Entasis Therapeutics	N/A	1.65	1.65
TRVN Trevena	N/A	2.42	2.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDS Aridis Pharmaceuticals	9.65%
ASLN ASLAN Pharmaceuticals	58.82%
CPIX Cumberland Pharmaceuticals	15.51%
ETTX Entasis Therapeutics	6.91%
TRVN Trevena	13.56%

Insider Ownership

Company	Insider Ownership
ARDS Aridis Pharmaceuticals	5.50%
ASLN ASLAN Pharmaceuticals	4.69%
CPIX Cumberland Pharmaceuticals	44.85%
ETTX Entasis Therapeutics	6.50%
TRVN Trevena	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDS Aridis Pharmaceuticals	30	53.32 million	50.39 million	Not Optionable
ASLN ASLAN Pharmaceuticals	30	2.04 million	1.95 million	Optionable
CPIX Cumberland Pharmaceuticals	80	14.96 million	8.25 million	Optionable
ETTX Entasis Therapeutics	51	47.85 million	44.74 million	Not Optionable
TRVN Trevena	40	959,000	841,000	Optionable

ARDS, ASLN, TRVN, CPIX, and ETTX Headlines

Recent News About These Companies

Softball: Conrad Weiser’s Alex Trevena earns statewide player of the year award; 5 other Berks players honored

July 8, 2025 | msn.com

Trevena, Inc. (TRVN) - Yahoo Finance

June 29, 2025 | finance.yahoo.com

Trevena Enters Securities Exchange Agreement with Investor

May 15, 2025 | tipranks.com

Berks sports roundup: Alex Trevena helps Conrad Weiser to 8-5 softball win

April 11, 2025 | readingeagle.comR

Vanessa Hudgens and Oliver Trevena Appear at Expo West for Caliwater

March 9, 2025 | msn.com

JMP Securities downgrades Trevena (TRVN) to a Hold

December 27, 2024 | markets.businessinsider.com

‘Plane’ Actor Oliver Trevena Signs With Untitled Entertainment

December 16, 2024 | yahoo.com

Lyme Regis town councillor John Trevena stand down

December 11, 2024 | bridportnews.co.ukB

Trevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

December 10, 2024 | zacks.com

Trevena appoints new financial chief

November 29, 2024 | investing.com

Trevena Appoints Katrine Sutton as New CFO

November 27, 2024 | tipranks.com

HC Wainwright & Co. Downgrades Trevena (TRVN)

November 16, 2024 | msn.com

Trevena, Inc. Navigates Financial Challenges and Strategic Changes

November 9, 2024 | msn.com

Chester County biopharm firm's latest layoffs impact its C-suite

November 7, 2024 | bizjournals.com

Trevena teeters in dangerous territory, terminating CEO and other execs amid strategic review

November 7, 2024 | fiercebiotech.comF

Trevena Reports Third Quarter 2024 Results and Provides Business Update

November 7, 2024 | globenewswire.com

Why Trevena (TRVN) Stock Is Down 43% Today

October 8, 2024 | msn.com

Trevena, Inc. Faces Delisting from Nasdaq

October 6, 2024 | msn.com

Trevena Announces Receipt of Nasdaq Delisting Notification

October 4, 2024 | globenewswire.com

Learn to Evaluate (TRVN) using the Charts

September 16, 2024 | news.stocktradersdaily.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Why Amazon Could Be About To Breakout To $250
By Sam Quirke | June 19, 2025
View Why Amazon Could Be About To Breakout To $250

ARDS, ASLN, TRVN, CPIX, and ETTX Company Descriptions

Aridis Pharmaceuticals NASDAQ:ARDS

$0.0001 +0.00 (+∞)

As of 09:34 AM Eastern

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.

ASLAN Pharmaceuticals NASDAQ:ASLN

$0.60 0.00 (0.00%)

As of 07/14/2025

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

Cumberland Pharmaceuticals NASDAQ:CPIX

$3.50 +0.10 (+2.94%)

Closing price 04:00 PM Eastern

Extended Trading

$3.48 -0.02 (-0.71%)

As of 04:23 PM Eastern

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Entasis Therapeutics NASDAQ:ETTX

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.

Trevena NASDAQ:TRVN

$0.93 +0.02 (+2.15%)

As of 10:02 AM Eastern

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time